Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore ...Middle East

First drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy SINGAPORE, Dec. 21, 2023 /PRNewswire/ -- Singapore-headquartered Juniper Therapeutix, a science-led healthcare company focused on commercializing novel therapies, today...

Hence then, the article about juniper therapeutics acquires exclusive rights for sar registration for anti viral covid 19 drug from ping an shionogi hong kong for singapore was published today ( Friday 22/12/2023 - 02:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Juniper Therapeutics Acquires Exclusive Rights for SAR Registration for Anti-Viral COVID-19 Drug from Ping An-Shionogi Hong Kong for Singapore )

Also on site :

• Ukraine-Russia war latest: Macron to deliver missile interceptors to Kyiv as Putin pulls ambassador from UK
• Log Cabin Republicans, un destacado grupo de gays conservadores, abandona la defensa de los derechos de las personas trans
• Iran-US war latest: Tehran warns of ‘earthquake-like’ retaliation over Trump’s ‘economic D-Day’ threats